Status:
COMPLETED
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Lead Sponsor:
AstraZeneca
Conditions:
Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Eligibility:
All Genders
Brief Summary
To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a ...
Detailed Description
To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a ...
Eligibility Criteria
Inclusion
- Patients with relapsed or refractory chronic lymphocytic leukemia (small lymphocytic lymphoma) who are treated with the product -
Exclusion
- None
- \-
Key Trial Info
Start Date :
June 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 4 2024
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04872621
Start Date
June 30 2021
End Date
September 4 2024
Last Update
September 2 2025
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan, D8224C00001
2
Research Site
Aichi, Japan
3
Research Site
Akita, Japan
4
Research Site
Aomori, Japan, D8224C00001